UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 20, 2007
La Jolla Pharmaceutical Company
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-24274
|
|
33-0361285 |
|
|
|
|
|
|
| (State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
| 6455 Nancy Ridge Drive, San Diego, California
|
|
92121 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On March 20, 2007, La Jolla Pharmaceutical Company (the “Company”) issued a press release
announcing updated interim antibody data for its ongoing double-blind, placebo-controlled
randomized Phase 3 trial of Riquent® (abetimus sodium), the Company’s drug candidate for
systemic lupus erythematosus. A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is filed with this report on Form 8-K:
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
|
|
|
99.1
|
|
Press Release, dated March 20, 2007 |